Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Suzhou Basecare Medical Corporation Limited
蘇州貝康醫療股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2170)

VOLUNTARY ANNOUNCEMENT
NMPA APPROVAL OF REGISTRATION APPLICATION FOR PGT-A KIT

This announcement is made by Suzhou Basecare Medical Corporation Limited (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business advancement of the Group.

The board of directors (the "**Board**") of the Company is pleased to announce that on March 13, 2026, the Company successfully obtained the national Class III medical device registration certificate for our pre-implantation genetic testing kit for aneuploidy (combined with probe-anchored polymerization sequencing method), a PGT-A kit based on the domestically developed high-throughput gene sequencing platform (registration certificate No.: Guo Xie Zhu Zhun 20263400529), becoming the first PGT-A kits based on a purely domestically developed sequencing platform in China. Such kit is suitable for IVF patients aged 35 and above, couples with chromosomal abnormalities, individuals who have experienced three or more failed embryo transfers or miscarriages and families who have previously given birth to children with chromosomal abnormalities. By analyzing the DNA of partial embryonic cells to detect chromosomal aneuploidy and assisting in clinical implantation decisions, it marks a breakthrough in the complete localization of the "equipment-reagents-analysis software" chain in China's assisted reproductive genetic testing field, injecting powerful "Chinese chips" into China's health industry.

The PGT-A kit can effectively reduce the risk of miscarriage and the incidence of birth defects by screening for chromosomal aneuploidy in embryos, and is a key support for the third-generation of IVF technology. The kit of the Company approved this time is the result of years of our technical research and development efforts, which has completed multi-center systematic validation in terms of detection accuracy, platform compatibility and clinical applicability, filling the gap in the application of purely domestically developed sequencing platforms in the PGT-A field and providing clinical practice with a more independent and controllable testing option.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Suzhou Basecare Medical Corporation Limited
Dr. Liang Bo
Chairman and General Manager

Suzhou, PRC, March 16, 2026

As at the date of this announcement, the Board comprises Dr. LIANG Bo, Mr. KONG Lingyin and Ms. JIANG Junchao as executive Directors; Mr. ZHAO Ye and Mr. WANG Weipeng as non-executive Directors; and Dr. KANG Xixiong, Mr. LAM Siu Wing and Dr. YEUNG Shu Biu William as independent non-executive Directors.